was founded in 2019 thanks to the intensive work with the PSL Valorisation team and the funding from . The start-up, a spin-off from ENS - PSL, was founded by Emmanuelle Martiano et Maximilien Levesque, a researcher at the ENS-PSL's chemistry department; Aqemia's strenght lies on the use of machine learning and unique algorithms derived from theoretical physics to invent innovative molecules.
On December 10, 2020, Aqemia received support and funding from Sanofi to apply its disruptive technology against COVID-19. The deeptech startup joined the battle against the Covid from the start and positioned its technology to design and test new molecules. Aqemia's research now benefit from the support of a leader in the pharmaceutic industry. As part of the agreement, Aqemia will apply its generative AI combined with its disruptive proprietary algorithms for affinity calculation between therapeutic targets and drug candidates against the coronavirus protease.
